Stardots completes a new share issue of SEK 15 million

Stardots AB (“Stardots” or “the Company”) has completed a new share issue of approx. SEK 15 million. A number of investors participated in the new share issue, including the existing shareholders VNV Global, Uppsala University Invest and Stockholm University Holding, as well as new investors such as the Beijer Foundation.

Stardots intends to use the net proceeds from the new share issue to further develop its digital health platform for Parkinson’s disease and prepare the company’s launch in the US and Europe.

“We are grateful for the support and trust from existing and new investors in this capital raise and are thrilled that they share the company’s vision to provide patients of neurological diseases with a better future.” says Daniel Petrini, CEO of Stardots.

Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease. More than 10 million people are affected worldwide. The most significant risk factor for Parkinson’s disease is age. With an increasing share of the population aged 65 and up, the number of Parkinson’s disease diagnosis are likely to rise. Costs for society are significant, estimated to be USD 15B and USD 50B in the EU and US, respectively, with direct treatment cost accounting for approximately 50% of the total.

Stardots’ vision is that its digital health platform ANLIVA™ will become a new standard for objective, equal, globally accessible, and cost-effective Parkinson’s care.

ANLIVA™, intends to provide accurate and accessible digital markers of Parkinson’s disease symptoms in addition to optimized treatment suggestions. ANLIVA™ supports the trend and ongoing shift to patient centered case with accessible, fast, and reliable symptom quantifications using state-of-the-art mathematical modelling.

Used together with pharma- and medtech-products, ANLIVA™ will offer a more individualized precision treatment. As an example, Stardots entered into a strategic collaboration with OnDosis in September 2022, a medical technology company spun off from AstraZeneca. OnDosis develops a unique device platform for flexible and individualized dosing of drugs. The collaboration combines the companies’ groundbreaking technologies and enables the development of unique products for the treatment of Parkinson’s disease.